# EDGAR Filing Document

**Accession Number:** 0001481504
**File Stem:** 0001477932-23-001086
**Filing Date:** 2023-2
**Character Count:** 113881
**Document Hash:** bcdc4e8fd5e10620c9e57288b566a737
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001086.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001477932-23-001086

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 57

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XERIANT, INC.
- **CENTRAL INDEX KEY:** 0001481504
- **STANDARD INDUSTRIAL CLASSIFICATION:** AIRCRAFT [3721]
- **IRS NUMBER:** 271519178
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54277
- **FILM NUMBER:** 23637028

**BUSINESS ADDRESS:**
- **STREET 1:** INNOVATION CENTRE #1, 3998 FAU BLVD.
- **STREET 2:** SUITE 309
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-491-9595

**MAIL ADDRESS:**
- **STREET 1:** INNOVATION CENTRE #1, 3998 FAU BLVD.
- **STREET 2:** SUITE 309
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Banjo & Matilda, Inc.
- **DATE OF NAME CHANGE:** 20131112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EASTERN WORLD SOLUTIONS, INC.
- **DATE OF NAME CHANGE:** 20121116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Encom Group, Inc.
- **DATE OF NAME CHANGE:** 20120420

?xml version="1.0" encoding="utf-8"?xeri_10q.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 10-Q**

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**For the quarterly period ended <u>December 31, 2022</u>**

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________.

Commission File Number: **000-54277**

---

| |
|:---|
| **XERIANT, INC.** |
| (Exact name of registrant as specified in its charter). |

---

---

| | |
|:---|:---|
| **Nevada** | **27-1519178** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **Innovation Centre 1**<br>**3998 FAU Boulevard, Suite 309**<br>**Boca Raton, Florida** | **33431** |
| (Address of principal executive offices) | (Zip code) |

---

Registrant's telephone number, including area code: **<u>(561) 491-9595</u>**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol | Name of exchange on which registered  |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, and an "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated Filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company  | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition 13(a) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of February 14, 2023, the Registrant had outstanding 376,933,144 shares of common stock.

**XERIANT, INC.** 

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **[Special Note regarding Forward-looking Statements](#spe)** | **[Special Note regarding Forward-looking Statements](#spe)** | 3 |
| **[PART I – Financial Information](#p1)** | **[PART I – Financial Information](#p1)** |  |
| [Item 1.](#i1) | [Condensed Consolidated Financial Statements (Unaudited)](#i1) | 4 |
| [Item 2.](#i2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2) | 5 |
| [Item 3.](#i3) | [Quantitative and Qualitative Disclosures about Market Risk](#i3) | 10 |
| [Item 4.](#i4) | [Controls and Procedures](#i4) | 10 |
| **[PART II – Other Information](#p2)** | **[PART II – Other Information](#p2)** |  |
| [Item 1.](#i1n) | [Legal Proceedings](#i1n) | 11 |
| [Item 1A.](#i1a) | [Risk Factors](#i1a) | 11 |
| [Item 2.](#i2n) | [Unregistered Sales of Equity Securities](#i2n) | 11 |
| [Item 3.](#i3n) | [Defaults Upon Senior Securities](#i3n) | 11 |
| [Item 4.](#i4n) | [Mine Safety Disclosures](#i4n) | 11 |
| [Item 5.](#i5) | [Other Information](#i5) | 11 |
| [Item 6.](#i6) | [Exhibits](#i6) | 12 |
| **[Signatures](#sin)** | **[Signatures](#sin)** | 13 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#tocc)* |

---

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This document contains certain statements of a forward-looking nature. Such forward-looking statements, including but not limited to statements regarding projected growth, trends and strategies, future operating and financial results, financial expectations and current business indicators are based upon current information and expectations and are subject to change based on factors beyond the control of the Company. Forward-looking statements typically are identified by the use of terms such as "look," "may," "should," "might," "believe," "plan," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The accuracy of such statements may be impacted by a number of risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including but not limited to those set forth herein and in our Annual Report on Form 10-K.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by the federal securities laws, we undertake no obligation to update forward-looking information. Nonetheless, the Company reserves the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this Report. No such update shall be deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other updates.

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#tocc)* |

---

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial statements**

**XERIANT, INC.**

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2022**

**(UNAUDITED)**

**INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| [Condensed Consolidated Balance Sheets as of December 31, 2022 (Unaudited) and June 30, 2022](#bs) | F-1 |
| [Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2022 and 2021 (Unaudited)](#sop) | F-2 |
| [Condensed Consolidated Statements of Stockholder's Equity for the three and six months ended December 31, 2022 and 2021 (Unaudited)](#stock) | F-3 |
| [Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2022 and 2021 (Unaudited)](#cf) | F-5 |
| [Notes to Unaudited Condensed Consolidated Financial Statements](#notes) | F-6 |

---

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#tocc)* |

---

---

| | | |
|:---|:---|:---|
| **XERIANT, INC.**  | **XERIANT, INC.**  | **XERIANT, INC.**  |
| **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** |
|  | **As of** <br>**December 31,**<br>**2022** | **As of**<br>**June 30,**<br>**2022** |
| Assets | (Unaudited) |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash  | $119593 | $1065945 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deposits  | 12546 | 12546 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in JV with Ebenberg LLC | 107928 | 57678 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaids | 10515 | 756 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 250582 | 1136925 |
| Property & equipment, net | 6263 | 4409 |
| Operating lease right-of-use asset | 106239 | 128342 |
| Total assets | $363084 | $1269676 |
| Liabilities & stockholders' deficit |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $157956 | $56836 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities, related party | 64000 | 22000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares to be issued | 75200 | 75200 |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible notes payable, net of discount | 5850000 | 3936185 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liability, current | 50647 | 48963 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 6197803 | 4139184 |
| Lease liability, long-term | 66938 | 92197 |
| Total liabilities | 6264741 | 4231381 |
| Commitments and contingencies (Note 9) |  |  |
| Stockholders' deficit |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred stock, $0.00001 par value; 100,000,000 authorized; 3,500,000 designated; 769,895 and 781,132 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively | 8 | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series B Preferred stock, $0.00001 par value; 100,000,000 authorized; 1,000,000 designated; 1,000,000 issued and outstanding at December 31, 2022 and June 30, 2022, respectively | 10 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.00001 par value; 5,000,000,000 shares authorized; 376,933,144 and 365,239,001 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively | 3769 | 3637 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock to be issued | 51950 | 51950 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid in capital | 19523605 | 16351806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (22668656) | (16571505) |
| &nbsp;&nbsp;&nbsp;&nbsp;Controlling interest | (3089314) | (164094) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-controlling interest | (2812343) | (2797611) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (5901657) | (2961705) |
| Total liabilities and stockholders' deficit | $363084 | $1269676 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

---

| |
|:---|
| F-1 |
| *[**Table of Contents**](#TOCF)* |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **XERIANT, INC.**  | **XERIANT, INC.**  | **XERIANT, INC.**  | **XERIANT, INC.**  | **XERIANT, INC.**  |
| **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  |
| **(UNAUDITED)** | **(UNAUDITED)** | **(UNAUDITED)** | **(UNAUDITED)** | **(UNAUDITED)** |
|  | **For the three months ended** | **For the three months ended** | **For the six months ended** | **For the six months ended** |
|  | **December 31, 2022** | **December 31, 2021** | **December 31, 2022** | **December 31, 2021** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | $340508 | $1120250 | $886077 | $2321252 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 78568 | 102484 | 168628 | 132025 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related party consulting fees | 118000 | 130925 | 212000 | 213425 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense |  | 2859644 |  | 5200219 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing expense | 1943 | 46623 | 8299 | 645218 |
| Total operating expenses | 539019 | 4259926 | 1275004 | 8512139 |
| Loss from operations | (539019) | (4259926) | (1275004) | (8512139) |
| Other expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount |  | (1264931) | (461842) | (1413959) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing fees |  |  |  | (43750) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (1625) |  | (4014) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from Ebenberg JV | (65722) |  | (115050) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | (689621) | (4) | (4259987) | (536) |
| Total other (expense) | (755343) | (1266560) | (4836879) | (1462259) |
| Net loss | (1294362) | (5526486) | (6111883) | (9974398) |
| Less net loss attributable to noncontrolling interest | (7307) | (2037053) | (14732) | (3214869) |
| Net income attributable to common stockholders | $(1287055) | $(3489433) | $(6097151) | $(6759529) |
| Net loss per common share - basic and diluted | $(0.00) | $(0.01) | $(0.02) | $(0.02) |
| Weighted average number of common shares outstanding - basic and diluted | 373345770 | 234451953 | 369415435 | 328392903 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

---

| |
|:---|
| F-2 |
| *[**Table of Contents**](#TOCF)* |

---

---

| |
|:---|
| **XERIANT, INC.**  |
| **CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT** |
| **FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2022** |
| **(UNAUDITED)** |

---

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series A**<br>**Preferred Stock** | **Series A**<br>**Preferred Stock** | **Series B**<br>**Preferred Stock** | **Series B**<br>**Preferred Stock** | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid in**<br>**Capital** | **Common stockto be**<br>**issued** | **Accumulated**<br>**Deficit** | **Non-Controlling**<br>**Interest** |<br>**Total** |
| Balance June 30, 2022 | **781132** | $**8** | **1000000** | $**10** | **365239001** | $**3637** | **16351806** | $**51950** | $**(16571505)** | $**(2797611)** | $**(2961705)** |
| Stock issued for services |  |  |  |  | 457143 | 5 | 47995 |  |  |  | 48000 |
| Conversion of Series A Preferred to Common Stock | (1000) |  |  |  | 1000000 | 10 | (10) |  |  |  |  |
| Fair value of warrants associated with convertible debt |  |  |  |  |  |  | 1918393 |  |  |  | 1918393 |
| Adjustment for rounding |  |  |  |  |  | 5 | (5) |  |  |  |  |
| Stock option compensation |  |  |  |  |  |  | 306170 |  |  |  | 306170 |
| Net Loss |  |  |  |  |  |  |  |  | (4810096) | (7425) | (4817521) |
| Balance September 30, 2022 | **780132** | $**8** | **1000000** | $**10** | **366696144** | $**3657** | **18624349** | $**51950** | $**(21381601)** | $**(2805036)** | $**(5506663)** |
| Conversion of Series A Preferred to Common Stock | (10237) |  |  |  | 10237000 | 102 | (102) |  |  |  |  |
| Fair value of warrants associated with convertible debt |  |  |  |  |  |  | 689621 |  |  |  | 689621 |
| Stock option compensation |  |  |  |  |  |  | 209747 |  |  |  | 209747 |
| Net Loss |  |  |  |  |  |  |  |  | (1287055) | (7307) | (1294362) |
| Balance December 31, 2022 | **769895** | $**8** | **1000000** | $**10** | **376933144** | $**3769** | **19523605** | $**51950** | $**(22668656)** | $**(2812343)** | $**(5901657)** |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

---

| |
|:---|
| F-3 |
| *[**Table of Contents**](#TOCF)* |

---

**XERIANT, INC.**

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY**

**FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2021**

**(UNAUDITED)**

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series A** <br>**Preferred Stock** | **Series A** <br>**Preferred Stock** | **Series B** <br>**Preferred Stock**  | **Series B** <br>**Preferred Stock**  | **Common Stock**  | **Common Stock**  | | | | | |
|  | **Shares** | **Amount**  | **Shares** | **Amount**  | **Shares** | **Amount**  | **Additional Paid in**<br>**Capital**  | **Common stock to be** <br> **issued**  | **Accumulated**<br>**Deficit** | **Non-Controlling** <br> **Interest**  | <br> **Total** |
| Balance June 30, 2021 | **788270** | **8** | **1000000** | **10** | **292815960** | **2925** | **4138194** | **51090** | **(3270235)** | **(216686)** | **705306** |
| Issuance of common stock committed in prior period |  |  |  |  | 400000 | 4 | 47996 | (48000) |  |  |  |
| Sale of common stock |  |  |  |  | 7500000 | 75 | 499925 | 1168500 |  |  | 1668500 |
| Shares issued as equity kicker |  |  |  |  | 250000 | 3 | 43750 |  |  |  | 43753 |
| Exercise of warrants |  |  |  |  | 4185000 | 41 | 125509 | 3000 |  |  | 128550 |
| Conversion of Series A Preferred to Common Stock | (4000) |  |  |  | 4000000 | 40 | (40) |  |  |  |  |
| Conversion of convertible notes and accrued interest |  |  |  |  | 10598544 | 106 | 176054 | (3090) |  |  | 173070 |
| Stock issued for services |  |  |  |  | 2825000 | 27 | 449173 | 91900 |  |  | 541100 |
| Stock option compensation |  |  |  |  |  |  | 1060324 |  |  |  | 1060324 |
| Fair value of beneficial conversion feature associated with convertible debt |  |  |  |  |  |  | 250000 |  |  |  | 250000 |
| Net Loss | - | - | - | - | - | - | - | - | (3270099) | (1177816) | (4447915) |
| Balance September 30, 2021 | **784270** | $**8** | **1000000** | $**10** | **322574504** | $**3221** | $**6790885** | $**1263400** | $**(6540334)** | $**(1394502)** | $**122688** |
| Issuance of common stock committed in prior period |  |  |  |  | 23266666 | 233 | 1162267 | (1162500) |  |  |  |
| Sale of common stock |  |  |  |  | 8200000 | 82 | 409918 |  |  |  | 410000 |
| Exercise of warrants |  |  |  |  | 123600 | 1 | 2999 | (3000) |  |  |  |
| Conversion of Series A Preferred to Common Stock | (3138) |  |  |  | 3138000 | 31 | (31) |  |  |  |  |
| Conversion of convertible notes and accrued interest |  |  |  |  |  |  |  | 250000 |  |  | 250000 |
| Stock issued for services |  |  |  |  | 900000 | 9 | 116095 |  |  |  | 116104 |
| Stock option compensation |  |  |  |  |  |  | 827221 |  |  |  | 827221 |
| Fair value of warrants associated with convertible debt |  |  |  |  |  |  | 2777081 |  |  |  | 2777081 |
| Fair value of beneficial conversion feature associated with convertible debt |  |  |  |  |  |  | 2365419 |  |  |  | 2365419 |
| Net Loss | - | - | - | - | - | - | - | - | (3489430) | (2037053) | (5526486) |
| Balance December 31, 2021 | **781132** | $**8** | **1000000** | $**10** | **358202770** | $**3577** | $**14451855** | $**347900** | $**(10029764)** | $**(3431555)** | $**1342031** |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

---

| |
|:---|
| F-4 |
| *[**Table of Contents**](#TOCF)* |

---

---

| | | |
|:---|:---|:---|
| **XERIANT, INC.**  | **XERIANT, INC.**  | **XERIANT, INC.**  |
| **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** | **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** | **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** |
| **(UNAUDITED)** | **(UNAUDITED)** | **(UNAUDITED)** |
|  | **For the six months ended** | **For the six months ended** |
|  | **December 31,** <br>**2022** | **December 31,** <br>**2021** |
| **Cash Flows from Operating Activities** |  |  |
| Net Loss | $(6111883) | $(9974398) |
| Adjustments to reconcile net loss to net |  |  |
| cash used by operating activities: |  |  |
| Depreciation and amortization | 713 | 83 |
| Stock option expense | 515917 | 1887545 |
| Stock issued for services | 48000 | 700954 |
| Loss on extinguishment of debt | 4259987 |  |
| Loss from joint venture investment  | (50250) |  |
| Amortization of debt discount | 461842 | 1413959 |
| Operating lease right of use asset | 22103 | 19899 |
| Changes in operating assets & liabilities: |  |  |
| Lease liabilities | (23575) | (20498) |
| Deposits and prepaids | (9759) | (1589) |
| Accounts payable and accrued liabilities | (98880) | (49476) |
| Accrued liability, related party | 42000 | 5000 |
| Accrued Expenses |  | 5520 |
| Net cash used by operating activities | (943785) | (6013001) |
| **Cash Flows from Investing Activities** |  |  |
| Purchase of property and equipment | (2567) | (4990) |
| Net cash used in investing activities | (2567) | (4990) |
| **Cash Flows from Financing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sale of common stock |  | 2078500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash from exercise of warrants |  | 128550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from convertible notes payable | - | 4958950 |
| Net cash provided by financing activities | - | 7166000 |
| Decrease in Cash | (946352) | 1148009 |
| Cash at beginning of period | 1065945 | 962540 |
| Cash at end of period | $119593 | $2110549 |
| Supplemental Cash Flow Information |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- |
| Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion of convertible notes payable and accrued interest | $- | $437246 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants issued with convertible notes payable | $- | $2777081 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial conversion feature arising from convertible notes payable | $- | $2615419 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants issued with convertible notes payable extinguishment | $2608014 | $- |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

---

| |
|:---|
| F-5 |
| *[**Table of Contents**](#TOCF)* |

---

**XERIANT, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**UNAUDITED**

**NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS**

**Company Overview**

Xeriant, Inc. ("Xeriant" or the "Company") is dedicated to the acquisition, development and commercialization of transformative technologies, including eco-friendly specialty materials which can be successfully deployed and integrated across multiple industry sectors, and disruptive innovations related to the emerging aviation market called Advanced Air Mobility, which include next-generation aircraft. We seek to partner with and acquire strategic interests in visionary companies that accelerate this mission.

The Company was incorporated in Nevada on December 18, 2009.

On April 16, 2019, the Company entered into a Share Exchange Agreement with American Aviation Technologies, LLC ("AAT"), an aircraft design and development company focused on the emerging segment of the aviation industry of autonomous and semi-autonomous vertical take-off and landing (VTOL) unmanned aerial vehicles (UAVs).

On September 30, 2019, the acquisition of AAT closed, and AAT became a subsidiary of the Company.

On June 22, 2020, the name of the Company was changed to Xeriant, Inc. in the State of Nevada and subsequently approved by FINRA effective July 30, 2020 for the name and symbol change (XERI).

On May 31, 2021, the Company entered into a Joint Venture Agreement with XTI Aircraft Company, to form a new company, called Eco-Aero, LLC, for purpose of completing the preliminary design of XTI's TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff and landing (eVTOL) fixed wing aircraft.

Effective April 2, 2022 and Amended November 7, 2022, the Company entered into a Joint Venture Agreement with Movychem s.r.o., a Slovakian limited liability company ("Movychem") setting forth the terms for the establishment of a joint venture (the "Joint Venture") to develop applications and commercialize a series of flame retardant products in the form of polymer gels, powders, liquids and pellets derived from technology developed by Movychem under the name Retacell™. The Joint Venture is organized as a Florida limited liability company under the name Ebenberg, LLC and is owned 50% by each of the Company and Movychem.

**Advanced Materials**

A primary focus of our Company is the acquisition and commercial exploitation of eco-friendly, advanced materials and chemicals which have applications across a broad range of industries and the potential to generate significant near-term revenue. The Company's commercialization strategy encompasses licensing arrangements and joint ventures with major industry players, which would allow for more rapid access to the market with reduced capital requirements and financial risk. In addition to providing the production and distribution infrastructure, these established partnering companies can streamline testing and certification and add brand recognition value. The advanced materials and chemicals may be sold as standalone products, enhancements to existing products, or used in the development of proprietary products under a new trademarked brand owned by the Company. The Company is exploring manufacturing and branding opportunities for specific products derived from advanced materials and chemicals acquired or developed, which would involve setting up production facilities, equipment, systems and supply chain. Our plan to source and acquire strategic interests in visionary companies developing, integrating, and commercializing critical breakthrough technologies is underway with our first advanced materials transaction closed in the second quarter of 2022.

---

| |
|:---|
| F-6 |
| *[**Table of Contents**](#TOCF)* |

---

Effective April 2, 2022, we entered into a Joint Venture Agreement with Movychem s.r.o, a Slovakian chemical company, setting forth the terms for a joint venture (referred to herein as the Movychem JV) to develop applications and commercialize a series of products which incorporate an internationally patented flame-retardant technology developed by Movychem under the trade name Retacell<sup>®</sup>. The Movychem JV, owned 50% by Xeriant and 50% by Movychem, subject to certain funding conditions, has been granted the exclusive worldwide rights to the intellectual property related to Retacell<sup>®</sup> and will be responsible for developing applications and commercializing products derived from Retacell<sup>®</sup>. Engineered over two decades, Retacell<sup>®</sup> is a versatile, biodegradable, non-toxic, high-performance thermal and fire protection chemical agent that is custom formulated for each application, based on the specific properties of the base material and the fire protection requirements. Retacell<sup>®</sup> can be applied as a coating, treatment, or infused during manufacturing into a variety of materials, including recycled plastics and wood-based fiber. In addition to becoming heat and fire resistant, the resulting Retacell<sup>®</sup>-enhanced materials are also water resistant.

On June 8, 2022, we announced the successful development of a multi-purpose, high-strength fire- and water-resistant composite panel made from a formulation of Retacell**<sup>®</sup>** and a cardboard fiber-reinforced polymeric resin, which can be sourced from recycled materials. The panel is fabricated through a compression molding process and may be produced or cut in varying thicknesses and sizes, including standard 48" x 96" sheets. Depending on the application, the panel can have different colors, textures or decorative finishes. Potential interior and exterior construction applications include walls, ceilings, flooring, framing, siding, roofing, and decking.

Xeriant, pursuant to the Services Agreement with the Movychem JV, is planning to buildout manufacturing facilities in the United States and Eastern Europe to meet the demand for Retacell<sup>®</sup> and Retacell<sup>®</sup>-infused products. The manufacturing facilities will be owned and operated by Xeriant and will wholesale product to customers licensed by the Movychem JV. We have identified potential sites, received bids for specialized manufacturing equipment, developed timetables related to the action plan, and hired a managing director with decades of experience to oversee the projects.

**Aerospace**

Another area of interest for our Company is the emerging aviation market called Advanced Air Mobility (AAM), the transition to more efficient, eco-friendly, automated and convenient flight operations enabled by the convergence of technological advancements in design and engineering, composite materials, propulsion systems, battery energy density and manufacturing processes. Next-generation aircraft being developed for this market offer low-cost, on-demand flight for passengers and cargo, utilizing lower altitude airspace and bypassing the traditional hub and spoke airport network with vertical takeoff and landing (VTOL) capabilities. Many of these lightweight aircraft are electrically powered through either hybrid or pure battery systems, which allows for quieter, low emission flights over urban areas, however with limited speed and range. The adoption and integration of niche aerial services through AAM is expected to provide benefits throughout the economy. We plan to partner with and acquire strategic interests in visionary companies that accelerate our mission of commercializing critical breakthrough AAM technologies which enhance performance, increase safety, and enable and support more efficient, autonomous, and sustainable flight operations, including electric and hybrid-electric passenger and cargo transport aircraft capable of vertical takeoff and landing. Our plan to source and acquire strategic interests in leading aerospace companies developing breakthrough VTOL aircraft began in the second quarter of 2021.

Effective May 27, 2021, we entered into a Joint Venture Agreement with XTI Aircraft Company ("XTI"), a privately owned OEM based in Englewood, Colorado for the purpose of completing the preliminary design of XTI's TriFan 600, a 5-passenger plus pilot, hybrid electric vertical takeoff and landing (eVTOL) fixed-wing aircraft.

Through our joint venture with XTI, (referred to hereinafter as the "XTI JV"), we were involved in the successful completion of the preliminary design of their TriFan 600 eVTOL aircraft. The TriFan 600 is being designed to become the fastest, longest-range VTOL aircraft in the world and the first commercial fixed-wing VTOL airplane, with current pre-orders and reservations of almost $7 billion in gross revenue upon delivery of those aircraft.

---

| |
|:---|
| F-7 |
| *[**Table of Contents**](#TOCF)* |

---

While the purpose of the XTI JV has been achieved, XTI and Xeriant continue to see value in the XTI JV for future collaboration in Advanced Air Mobility. Should XTI and Xeriant determine it is in their best interest to terminate the XTI JV, then it will be dissolved. Should the XTI JV be dissolved, as of October 18, 2022, Xeriant would receive 5.5% equity ownership of XTI.

Management believes that our holding and operating company structure has several advantages and will enable us to grow rapidly, acquiring assets primarily through acquisitions, joint ventures, strategic investments, and licensing arrangements. As a publicly traded company, we offer our subsidiaries such benefits as improved access to capital, higher valuations and lower risk through the shared ownership of a diversified portfolio, while allowing these entities to maintain independence in their distinct operations to focus on their fields of expertise. Cost savings and efficiencies may be realized from sharing non-operational functions such as finance, legal, tax, sales & marketing, human resources, purchasing power, as well as investor and public relations.

Additionally, we are leveraging our relationship with Florida Atlantic University to provide a collaborative research arm for technologies that require additional validation and the backing of a respected research institution for credibility. The university also may provide access to various grants through the SBIR (Small Business Innovation Research), STTR (Small Business Technology Transfer, NSF (National Science Foundation) and other programs, and if warranted, introductions into a number of government agencies, such as DOD (Department of Defense) and DARPA (Defense Advanced Research Projects Agency). We are pursuing strategic alliances with companies that provide complementary technologies and access to new markets.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

<u>Basis of Presentation</u>

The consolidated financial statements, which include the accounts of the Company, American Aviation Technologies, LLC, and Eco-Aero, LLC, its subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP). All significant intercompany balances and transactions have been eliminated. The consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The Financial Statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("GAAP") and presented in US dollars. The fiscal year end is June 30.

<u>Going Concern</u>

The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At December 31, 2022 and June 30, 2022, the Company had $119,593 and $1,065,945 in cash and $5,947,221 and $3,002,259 in negative working capital, respectively. For the six months ended December 31, 2022 and 2021, the Company had a net loss of $6,111,883 and $9,974,398, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's existence is dependent upon management's ability to develop profitable operations and resolve its liquidity problems.

---

| |
|:---|
| F-8 |
| *[**Table of Contents**](#TOCF)* |

---

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

<u>Principles of Consolidation</u>

The consolidated financial statements include the accounts of Xeriant, Inc., American Aviation Technologies, LLC, and Eco-Aero, LLC. All significant intercompany balances and transactions have been eliminated.

<u>Use of Estimates</u>

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.

<u>Fair Value Measurements and Fair Value of Financial Instruments</u>

The Company adopted ASC Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2: Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3: Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

The inputs to the valuation methodology of stock options and warrants were under level 3 fair value measurements.

<u>Cash and Cash Equivalents</u>

For purposes of the Statements of Cash Flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has no cash equivalents.

<u>Convertible Debentures</u>

If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature ("BCF"). A BCF is recorded by the Company as a debt discount pursuant to ASC Topic 470-20 "Debt with Conversion and Other Options." In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense, over the life of the debt. During the year ended June 30, 2022, the Company recorded a BCF in the amount of $2,615,419.

---

| |
|:---|
| F-9 |
| *[**Table of Contents**](#TOCF)* |

---

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

<u>Stock-based Compensation</u>

The Company measures the cost of employee services received in exchange for equity incentive awards based on the grant date fair value of the award. The Company uses the Black-Scholes valuation model to calculate the fair value of stock options granted to employees or consultants. Stock-based compensation expense is recognized over the period during which the employee is required to provide services in exchange for the award, which is usually the vesting period.

<u>Research and Development Expenses</u>

Expenditures for research and development are expensed as incurred. The Company incurred research and development expenses of $0 and $5,200,219 for the six months ended December 31, 2022 and 2021, respectively.

<u>Advertising and Marketing Expenses</u>

The Company expenses advertising and marketing costs as they are incurred. The Company recorded advertising expenses in the amount of $21,421 and $164,713 for the six months ended December 31, 2022 and 2021, respectively.

<u>Income Taxes</u>

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more likely than not of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our consolidated federal tax return and any state tax returns are not currently under examination.

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes ("ASC 740-10") for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

*Basic Income (Loss) Per Share*

Under the provisions of ASC 260, "Earnings per Share," basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations.

---

| |
|:---|
| F-10 |
| *[**Table of Contents**](#TOCF)* |

---

The table below presents the computation of basic and diluted earnings per share for the six months ended December 31, 2022 and 2021:

---

| | | |
|:---|:---|:---|
|  | **For the six months ended December 31, 2022** | **For the six months ended December 30, 2021** |
| **Numerator:** |  |  |
| Net loss | $(6097151) | $(6759529) |
| **Denominator:** |  |  |
| Weighted average common shares outstanding—basic | 369415435 | 328392903 |
| Dilutive common stock equivalents |  |  |
| Weighted average common shares outstanding—diluted | 369415435 | 328392903 |
| Net loss per share: |  |  |
| Basic | $(0.02) | $(0.02) |
| Diluted | $(0.02) | $(0.02) |

---

**NOTE 3 – JOINT VENTURE**

<u>JV with XTI Aircraft</u>

On May 31, 2021, the Company entered into a Joint Venture Agreement (the "Agreement") with XTI Aircraft Company ("XTI"), a Delaware corporation, to form a new company, called Eco-Aero, LLC (the "JV"), a Delaware limited liability company, with the purpose of completing the preliminary design of XTI's TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff, and landing (eVTOL) fixed wing aircraft. Under the Agreement, Xeriant is contributing capital, technology, and strategic business relationships, and XTI is contributing intellectual property licensing rights and know-how. XTI and the Company each own 50 percent of the JV. The JV is managed by a management committee consisting of five members, three appointed by the Company and two by XTI. The Agreement was effective on June 4, 2021, with an initial deposit of $1 million into the JV. Xeriant's financial commitment is for up to $10 million, contributed as required by the aircraft development timeline and budget. Preliminary design review was substantially completed for the TriFan 600 aircraft in early 2022. As of December 31, 2022, the Company had contributed $5,479,547 towards the XTI JV.

The Company analyzed the transaction under ASC 810 *Consolidation*, to determine if the joint venture classifies as a Variable Interest Entity ("VIE"). The Joint Venture qualifies as a VIE based on the fact the JV does not have sufficient equity to operate without financial support from Xeriant. According to ASC 810-25-38, a reporting entity shall consolidate a VIE when that reporting entity has a variable interest (or combination of variable interests) that provides the reporting entity with a controlling financial interest on the basis of the provisions in paragraphs 810-10-25-38A through 25-38J. The reporting entity that consolidates a VIE is called the primary beneficiary of that VIE. According to the JV operating agreement, the ownership interests are 50/50. However, the agreement provides for a Management Committee of five members. Three of the five members are from Xeriant. Additionally, Xeriant has an obligation to invest $10,000,000 into the JV. As such, Xeriant has substantial capital at risk. Based on these two factors, the conclusion is that Xeriant is the primary beneficiary of the VIE. Accordingly, Xeriant has consolidated the VIE.

---

| |
|:---|
| F-11 |
| *[**Table of Contents**](#TOCF)* |

---

<u>JV with Movychem</u>

On April 2, 2022 the Company entered into a Joint Venture Agreement with Movychem s.r.o., a Slovakian limited liability company setting forth the terms for the establishment of a joint venture (the "Joint Venture") to develop applications and commercialize a series of flame-retardant products in the form of polymer gels, powders, liquids and pellets derived from technology developed by Movychem under the name Retacell<sup>™</sup>. The Joint Venture is organized as a Florida limited liability company under the name Ebenberg, LLC and is owned 50% by each of the Company and Movychem.

For its capital contribution to the Joint Venture, pursuant to a Patent and Exclusive License and Assignment Agreement (the "Patent Agreement"), Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell exclusive of all patents, and the Company is contributing the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than six months from the Effective Date (Amended to February 15, 2023, as per Amended Agreement). As of December 31, 2022, the Company had two payments pending of $25,000 each, subject to satisfaction by Movychem of the terms of the Amendment to Joint Venture Agreement with Movychem. The Company is currently in discussions with Movychem with the intent of extending the February 15, 2023 date. At such time as the Company makes its $2,000,000 payment (and assuming the Company is current with its then monthly capital contributions), pursuant to the Patent Agreement, Movychem will transfer all of its rights, title and interest to all of the patents related to Retacell for an amount equal to aggregate cash contributions of the Company to the Joint Venture plus 40% of all royalty payments received by the Joint Venture for the licensing of Retacell products. Pending assignment of the patents to the Joint Venture, pursuant to the Patent Agreement, Movychem has granted to the Joint Venture an exclusive worldwide license under the patents.

Concurrently with the execution of the Joint Venture Agreement, the Joint Venture will provide to the Joint Venture technical services related to the exploitation of the Retacell intellectual property and corporate, marketing, business development, communications and administrative services as requested by the Joint Venture in exchange for 40% of all royalty payments received by the Joint Venture for the licensing of Retacell products.

Under the Joint Venture Agreement, the Company has agreed to grant to certain individuals affiliated with Movychem five-year warrants (the "Warrants") to purchase an aggregate of 170,000,000 shares of the Company's common stock at an exercise price of $0.01 per share with vesting depending on the satisfaction of various milestones as described therein.

The Joint Venture Agreement grants to Movychem the right to dissolve the Joint Venture in the event that the Company fails to make any of its capital contributions in which case the Joint Venture will be required to grant back to Movychem all joint venture intellectual property and the assignment to Movychem of any outstanding licenses. Additionally, the Services Agreement will be amended to provide that the 40% of royalties to be paid by to the Company will be limited to licensees who were first introduced to the Joint Venture or Movychem, as the case may be.

The Company analyzed the transaction under ASC 810 Consolidation, to determine if the joint venture classifies as a Variable Interest Entity ("VIE"). The Joint Venture qualifies as a VIE based on the fact the JV does not have sufficient equity to operate without financial support from both parties. According to ASC 810-25-38, a reporting entity shall consolidate a VIE when that reporting entity has a variable interest (or combination of variable interests) that provides the reporting entity with a controlling financial interest on the basis of the provisions in paragraphs 810-10-25-38A through 25-38J. The reporting entity that consolidates a VIE is called the primary beneficiary of that VIE. According to the JV operating agreement, the ownership interests are 50/50 and the agreement provides for a Management Committee of five members. Two of the five members are from Xeriant and Movychem, respectively and one is appointed by mutual agreement of the parties. Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell exclusive of all patents, and the Company is contributing cash. As such, both parties do not have substantial capital at risk. Based on these two factors, the conclusion is that no one is the primary beneficiary of the VIE. Accordingly, Xeriant has not consolidated the VIE.

As of December 31, 2022 and June 30, 2022, the Company contributed $280,656 and $115,356 to the joint venture, respectively.

---

| |
|:---|
| F-12 |
| *[**Table of Contents**](#TOCF)* |

---

**NOTE 4 – CONCENTRATION OF CREDIT RISKS**

The Company maintains accounts with financial institutions. All cash in checking accounts is non-interest bearing and is fully insured by the Federal Deposit Insurance Corporation (FDIC). At times, cash balances may exceed the maximum coverage provided by the FDIC on insured depositor accounts. The Company believes it mitigates its risk by depositing its cash and cash equivalents with major financial institutions. On December 31, 2022 and June 30, 2022, the Company had $0 and $811,429 in excess of FDIC insurance, respectively.

**NOTE 5 – OPERATING LEASE RIGHT-OF-USE ASSET AND OPERATING LEASE LIABILITY**

The Company leases 2,911 square feet of office space located in the Research Park at Florida Atlantic University, Innovation Centre 1, 3998 FAU Boulevard, Suite 309, Boca Raton, Florida. The Company entered into a lease agreement commencing on November 1, 2019 through January 1, 2025 in which the first three months of rent were abated. Due to the COVID-19 pandemic, the company decided to have all employees work from home and intends to build out the office space by the end of March 2023 to allow employees to work from the office in April of 2023. The following table illustrates the base rent amounts over the term of the lease:

**Base Rent Periods**

---

| | |
|:---|:---|
| November 1, 2019 to October 31, 2020 | $4367 |
| November 1, 2020 to October 31, 2021 | $4498 |
| November 1, 2021 to October 31, 2022 | $4633 |
| November 1, 2022 to October 31, 2023 | $4772 |
| November 1, 2023 to October 31, 2024 | $4915 |
| November 1, 2024 to January 31, 2025 | $5063 |

---

Operating lease right-of-use asset and liability are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of our leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease term. Since the common area maintenance expenses are expenses that do not depend on an index or rate, they are excluded from the measurement of the lease liability and recognized in other general and administrative expenses on the statements of operations. At inception the Company paid prepaid rent in the amount of $4,659, which was netted against the operating lease right-of-use asset balance until it was applied in February 2020.

---

| | |
|:---|:---|
| **Right-of-use asset is summarized below:** | |
|  |<br>**December 31, 2022** |
| Office lease | $220448 |
| Less: accumulated amortization | (114209) |
| Right - of- use asset, net | $106239 |

---

---

| |
|:---|
| F-13 |
| *[**Table of Contents**](#TOCF)* |

---

---

| | |
|:---|:---|
| **Operating lease liability is summarized below:** | **Operating lease liability is summarized below:** |
|  | **December 31,** <br>**2022** |
| Office lease | $117585 |
| Less: current portion | (50647) |
| Long term portion | 66938 |
| **Maturity of the lease liability is as follows:** |  |
| Fiscal year ending June 30, 2023 | 30491 |
| Fiscal year ending June 30, 2024 | 62201 |
| Fiscal year ending June 30, 2025 | 37112 |
|  | 129803 |
| Present value discount | (12218) |
| Lease liability | $117585 |

---

**NOTE 6 – CONVERTIBLE NOTES PAYABLE**

The carrying value of convertible notes payable, net of discount, as of December 31, 2022 and June 30, 2022 was $5,850,000 and $3,936,185, respectively.

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **June 30,** |
| **Convertible Notes Payable** | **2022** | **2022** |
| Convertible notes payable issued October 27, 2021 (0% interest) – Auctus Fund LLC | $5850000 | $6050000 |
| Total face value | 5850000 | 6050000 |
| Less unamortized discount | - | (2113815) |
| Carrying value | $5850000 | $3936185 |

---

Between September 27, 2019 and August 10, 2021, the Company issued convertible notes payable with an aggregate face value of $892,300, of which $342,950 were issued by our subsidiary AAT. The notes have a coupon rate of 6% and maturity dates between three and six months. The agreements provided the holder has the option to convert the principal balance and any accrued interest to common stock of the Company. In the event the holder does not elect to convert the note prior to maturity, the note will automatically convert to common stock. Of the $892,300, $342,950 is convertible at $.0033 per share, $87,000 is convertible at $0.025 per share, $180,550 is convertible at $.03 per share, $31,800 is convertible at $0.003 per share, and the remaining $250,000 is convertible at $.06 per share. All these convertible notes payable have been converted as of December 31, 2021. During the six months ended December 31, 2021, the Company recorded amortization of debt discount related to these notes in the amount of $1,413,959 and interest expense of $4,014.<br>

---

| |
|:---|
| F-14 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Auctus Fund, LLC Senior Secured Note</u>

On October 27, 2021, the Company issued a convertible note payable with Auctus Fund, LLC (the "Auctus Note") with the principal sum of $6,050,000, which amount is the $5,142,500 actual amount of the purchase price, hereof plus an original issue discount in the amount of $907,500 and to pay interest on the unpaid principal amount hereof at the rate of zero percent per annum from the issue date until the note becomes due and payable, and $433,550 for professional fees in completing the transactions. The note has a maturity date of twelve months. The agreement provides the holder has the option to convert the principal balance and any accrued interest to common stock of the Company at a conversion price of lesser of (i) $0.1187 or (ii) 75% of the offering price per share divided by the number of shares of common stock. The Auctus Note is secured by the grant of a first priority security interest in the assets of the Company.

In connection with the notes, the Company issued warrants indexed to an aggregate 50,968,828 shares of common stock. The warrants have a term of five years and an exercise price of $0.1187. The warrants were recorded at fair value of $2,777,081 to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the debt proceeds. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants. The Company estimates the volatility of its stock based on the average of three similar size public companies peer group historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon bond for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to their remaining contractual term.

The Company was required to determine if the debt contained a beneficial conversion feature ("BCF"), which is based on the intrinsic value on the date of issuance. The Company recorded $2,365,419 conversion feature in additional paid-in capital. The BCF resulted in a debt discount and are amortized over the life of the note.

Effective July 26, 2022, the Company entered into an Amendment to Senior Secured Promissory Note (the "Amendment") with Auctus Fund, LLC ("Auctus") pursuant to which the parties agreed to amend the Company's Senior Secured Convertible Promissory Note in the principal amount of $6,050,000 dated October 27, 2021 (the "Note") issued to Auctus. The Amendment (i) extended the maturity date of the Note to November 1, 2022 and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company's common stock to a national securities exchange to November 1, 2022. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of Common Stock dated July 26, 2022 (the "Warrant") at an exercise price of $0.09 per share; (ii) make a prepayment of the Note in the amount of $100,000; and (iii) cause a director of the Company to cancel his 10b-5(1) Plan. The Company tested the modification under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $3,570,366. The loss on extinguishment was determined as follows:

---

| | | |
|:---|:---|:---|
| **Reacquisition Price:** |  |  |
| Modified convertible debt instrument  |  | 5950000 |
| Fair value of warrants  |  | 1918393 |
| Cash payment  |  | 100000 |
| **Carrying Value of Original Instrument** |  |  |
| Original convertible debt instrument  | 6050000 |  |
| Debt discount - warrant  | (707585) |  |
| Original issue discount  | (341692) |  |
| Debt discount - BCF  | (602696) |  |
| Carrying value of original debt  |  | 4398027 |
| Loss on extinguishment  |  | 3570366 |

---

Effective December 27, 2022, the Company entered into an Amendment to Senior Secured Promissory Note (the "Amendment") with Auctus Fund, LLC ("Auctus") pursuant to which the parties agreed to amend the Company's Senior Secured Convertible Promissory Note in the principal amount of $6,050,000 dated October 27, 2021 (the "Note") issued to Auctus. The Amendment (i) extended the maturity date of the Note to March 15, 2023 and (ii) extended the dates for the completion of the acquisition of XTI Aircraft and the uplist of the Company's common stock to a national securities exchange to March 15, 2023. In consideration of the Amendment, the Company agreed to (i) grant to Auctus a new Warrant to purchase 25,000,000 shares of Common Stock dated December 27, 2022 (the "Warrant") at an exercise price of $0.09 per share; and (ii) make a prepayment of the Note in the amount of $50,000 on January 15, 2023 and $50,000 on February 15, 2023 The Company tested the modification under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification resulted in a loss on an extinguishment in the amount of $689,621. The loss on extinguishment was determined as follows:

---

| | |
|:---|:---|
| **Reacquisition Price:** |  |
| Modified convertible debt instrument  | 5850000 |
| Fair value of warrants  | 689621 |
| Accrued Short-term Liability | 100000 |
| **Carrying Value of Original Instrument** |  |
| Carrying value of original debt  | 5,950,000 |
| Loss on extinguishment  | 689621 |

---

For the six months ended December 31, 2022, the Company recorded $461,482 in amortization of debt discount related to the Auctus note. As of December 31, 2022 and June 30, 2022, the carrying value of the Auctus note was $5,850,000 and $3,936,185, respectively.

**NOTE 7– RELATED PARTY TRANSACTIONS**

*Consulting fees*

During the six months ended December 31, 2022 and 2021, the Company recorded $100,000 and $74,000 respectively, in consulting fees to Ancient Investments, LLC, a Company owned by the Company's CEO, Keith Duffy and the Company's Executive Director of Corporate Operations, Scott Duffy. As of December 31, 2022, and June 30, 2022, $15,000 and $22,000 was recorded in accrued liabilities.

For the six months ended December 31, 2022 and 2021, the Company recorded $52,000 and $52,000 respectively, in consulting fees to Edward DeFeudis, a Director of the Company. As of December 31, 2022, and June 30, 2022, $10,000 and $0 was recorded in accrued liabilities.

During the six months ended December 31, 2022 and 2021, the Company recorded $35,000 and $37,000 respectively, in consulting fees to AMP Web Services, a Company owned by the Company's CTO, Pablo Lavigna. As of December 31, 2022 and June 30, 2022, $7,000 and $7,000 was recorded in accrued liabilities.

During the six months ended December 31, 2022 and 2021, the Company recorded $15,000 and $15,000 respectively, in consulting fees to Keystone Business Development Partners, a Company owned by the Company's CFO, Brian Carey.

---

| |
|:---|
| F-15 |
| *[**Table of Contents**](#TOCF)* |

---

**NOTE 8 – COMMITMENTS AND CONTINGENCIES**

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, *Contingencies*. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals.

*Joint Venture*

In connection with the Eco-Aero, LLC Joint Venture, discussed in Note 3, the Company has the right to invest up to $10,000,000 into the joint venture.

*Financial Advisory Agreements*

On August 10, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments:

---

| |
|:---|
| to issue 500,000 shares payable at the date of the agreement, 500,000 shares payable three months from the date of the agreement, 500,000 shares payable nine months from the date of the agreement. |
| Pay a financing fee of 1.5% of gross proceeds received by the Company up to $100,000,000; a financing fee of 1.25% of gross proceeds received by the Company from $100,000,000-$200,000,000, and a financing fee of 1% of gross proceeds received by the Company over $200,000,000 |
| M&A fee of 1.5% of the value of a business or asset sold up to $50,000,000; an M&A fee of 1.25% of value of a business or asset sold from $50,000,000-$100,000,000, an M&A fee of 1% of value of a business or asset sold from $100,000,000-$200,000,000, and an M&A fee of 0.5% of value of a business or asset sold over $200,000,000 |

---

During the year ended June 30, 2022, the Company issued all 1,500,000 shares under the agreement.

On August 19, 2021, the Company entered into an Advisory Agreement with an outside firm to assist the Company with fundraising activities. In connection with the agreement, the Company has the following commitments:

---

| |
|:---|
| Issue 2,225,000 common shares payable at the date of the agreement, and 2,225,000 common shares payable upon an uplisting of the Company's common stock to a national exchange. |
| Pay a cash fee of seven percent 7% of the amount of capital raised, invested or committed; and deliver a warrant (the "Agent Warrant") to purchase shares of the Common Stock equal to seven percent (7%) of the number of shares of Common Stock underlying the securities issued in the Financing. |
| Pay a cash fee for entering into a transaction including, without limitation, a merger, acquisition or sale of stock or assets equal to one- and one-half percent (1.5%), or in the event a transaction is consummated with a party that was in communication with the Company prior to the date of this contract, then the fee shall equal one half percent (0.5%). |

---

During the year ended June 30, 2022, the Company issued the initial 2,225,000 shares.

---

| |
|:---|
| F-16 |
| *[**Table of Contents**](#TOCF)* |

---

*Litigation*

On September 1, 2021, Xeriant Inc. brought a cause of action in the Southern District of Florida against a former shareholder for claims, including but not limited to, breach of contract, misrepresentation, and asserting claims to recoup monetary and in-kind distributions made to the shareholder by the Company. The defendant submitted an affirmative defense and counterclaim on October 29, 2021.

***Board of Advisors Agreements***

The Company has entered into advisor agreements with various advisory board members. The agreements provide for the following:

On October 27, 2020, the Company agreed to issue 300,000 common shares immediately, 2-year cashless warrants to purchase 300,000 common shares at the current price, and $2,500 per meeting paid 50% in cash and 50% in common shares.

On January 18, 2021, the Company agreed to issue 50,000 common shares, two-year cashless warrants to purchase 25,000 common shares at the current price, and $2,500 per meeting paid in cash, common shares, or a combination.

On January 22, 2021, the Company agreed to issue 50,000 common shares, two-year cashless warrants to purchase 25,000 common shares at the current price, and $2,500 per meeting paid in cash, common shares, or a combination.

On March 7, 2021 the Company paid an advisor $2,500 and issued 50,000 common shares.

On July 1, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, and for each of the following three years (beginning July 1, 2022), an option to purchase an additional 1,000,000 common shares per year thereafter at a 25% discount to the average market price for the preceding 10 trading days.

On July 6, 2021, provided an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 250,000 common shares issued upon a strategic partnership with a major airline, $2,500 per formal meeting paid in common shares, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service.

On July 28, 2021, the Company agreed to issue 250,000 common shares immediately, an option to purchase 5,000,000 common shares at $0.12 per share, vesting quarterly over 24 months, a bonus of 5,000,000 common shares for bringing in a strategic partner that significantly strengthens the Company's market position, $2,500 per formal meeting paid in cash, common shares or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service

On August 9, 2021, the Company agreed to issue 50,000 common shares, $2,500 per meeting paid in cash, common shares, or a combination, and an additional bonus of $25,000 paid in common shares issued at the end of each year of service.

On August 20, 2021, the Company agreed to issue 100,000 common shares, and $2,500 per meeting paid in cash, common shares, or a combination, an additional bonus of $25,000 paid in common shares issued at the end of each year of service, an option to purchase 4,000,000 common shares at $0.12 per share, vesting quarterly over 24 months.

---

| |
|:---|
| F-17 |
| *[**Table of Contents**](#TOCF)* |

---

On January 20, 2022, the Company agreed to issue 250,000 common shares, and $5,000 paid on a monthly basis, for a period of three months, and an option to purchase 2,250,000 common shares at $0.12 per share, vesting immediately.

On March 28, 2022, the Company agreed to issue 150,000 common shares vested monthly over one year, and $2,500 per meeting paid in cash, and additional bonus of $25,000 paid in common shares issued at the end of each year of service.

**NOTE 9 – EQUITY**

*Common Stock*

As of December 31, 2022 and June 30, 2022, the Company had 5,000,000,000 shares of common stock authorized with a par value of $,0.00001. There were 376,933,144 and 365,239,001 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively.

*Fiscal Year 2022 Issuances*

During the year ended June 30, 2022 in connection with one of the subscription agreements, the Company issued 250,000 shares as an equity kicker valued at $43,753, which has been expensed as a financing costs.

During the year ended June 30, 2022, the Company issued 4,308,600 shares of common stock as a result of warrant exercises in the aggregate proceeds of $128,550.

During the year ended June 30, 2022, the Company issued 4,685,615 shares of common stock for services, valued at $761,954.

During the year ended June 30, 2022, the Company sold 39,366,666 shares of common stock for aggregate proceeds of $2,078,500.

During the year ended June 30, 2022, the Company issued 7,138,000 shares of common stock in exchange for the conversion of 7,138 shares of Series A Preferred Stock.

During the year ended June 30, 2022, the Company issued 10,598,544 shares of common stock for the conversion of $167,550 in principal and $4,985 in accrued interest. This resulted in a loss on extinguishment of debt in the amount of $535.

During the year ended June 30, 2022, the Company issued 4,229,680 shares of common stock for the conversion of $250,000 principal balance of convertible notes payable and $3,749 accrued interest.

During the year ended June 30, 2022, the Company issued 845,936 shares of common stock in exchange for the inducement to the convertible notes holders to convert at fair value of $134,927.

*Six Months Ended December 31, 2022*

On July 11, 2022, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A Preferred Stock.

On July 13, 2022, the Company issued 457,143 shares to a consultant for services valued at $48,000.

On October 24, 2022, the Company issued 10,237,000 shares of common stock in exchange for the conversion of 10,237 shares of Series A Preferred Stock.

---

| |
|:---|
| F-18 |
| *[**Table of Contents**](#TOCF)* |

---

*Common Stock to be Issued*

During the year ended June 30, 2022, the Company sold 200,000 shares of common stock for aggregate proceeds of $6,000, or $0.03 per share. As of June 30, 2022, these shares are categorized in common stock to be issued.

During the year ended June 30, 2022, the Company agreed to pay a consultant 250,000 shares in exchange to $45,950 in services. As of June 30, 2022, these shares are categorized in common stock to be issued.

*Series A Preferred Stock*

There are 100,000,000 shares authorized as preferred stock, of which 3,500,000 are designated as Series A Preferred Stock having a par value of $0.00001 per share. The Series A preferred stock has the following rights:

---

| |
|:---|
| <u>Voting</u>: The preferred shares shall be entitled to 100 votes to every one share of common stock. |
| <u>Dividends:</u> The Series A Preferred Stockholders are treated the same as the Common Stock holders except at the dividend on each share of Series A Convertible Preferred Stock is equal to the amount of the dividend declared and paid on each share of Common Stock multiplied by the Conversion Rate. |
| <u>Conversion</u>: Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time into shares of Common Stock on a 1:1,000 basis. |
| The shares of Series A Preferred Stock are redeemable at the option of the Corporation at any time after September 30, 2022 upon not less than 30 days written notice to the holders. It is not mandatorily redeemable. |

---

As of December 31, 2022, and June 30, 2022, the Company has 769,895 and 781,132 of shares of Series A Preferred Stock issued and outstanding, respectively.

On February 15, 2021, in accordance with Florida Law and conversations with counsel, the Board of Directors of the Company rescinded 990,000 Series A Preferred Shares, which represented all preferred shares issued to one of the shareholders in the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc. entered into on April 19, 2019, due to breach of contract.

During March of 2021, the remaining former members of American Aviation Technologies, LLC agreed to allow the Company to rescind an aggregate of 1,250,001 of their 1,760,000 Series A Preferred Shares issued pursuant to the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc., as a result of said breach. As a result of the cancellation, the Company reduced the investment in AAT by the value of these preferred shares.

On March 27, 2021, Spider Investments, LLC returned 41,000 Series A Preferred Shares to the treasury of the Company.

On July 11, 2022, the Company issued 1,000,000 shares of common stock in exchange for the conversion of 1,000 shares of Series A Preferred Stock.

On October 24, 2022, the Company issued 10,237,000 shares of common stock in exchange for the conversion of 10,237 shares of Series A Preferred Stock.

---

| |
|:---|
| F-19 |
| *[**Table of Contents**](#TOCF)* |

---

*Series B Preferred Stock*

On March 25, 2021, the Certificate of Designation for the Series B Preferred was recorded by the State of Nevada. There are 100,000,000 shares authorized as preferred stock, of which 1,000,000 are designated as Series B Preferred Stock having a par value of $0.00001 per share. The Series B preferred stock is not convertible, does not have any voting rights and no liquidation preference.

During the year ended June 30, 2021, the Company issued 1,000,000 shares of Series B Preferred Stock to the Company's CEO as part of his employment agreement.

*Stock Options*

In connection with certain advisory board compensation agreements, the Company issued an aggregate 21,250,000 options at an exercise price of $0.12 per share for the year ended June 30, 2022. These options vest quarterly over twenty-four months and have a term of three years. The grant date fair value was $3,964,207. The Company recorded compensation expense in the amount of $515,917 and $1,887,545 for these options for the six months ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there was $186,199 of total unrecognized compensation cost related to non-vested portion of options granted.

As of December 31, 2022, there are 21,250,000 options outstanding, of which 15,375,000 are exercisable. The weighted average remaining term is 1.38 years.

Significant inputs and results arising from the Black-Scholes process are as follows for the options:

---

| | | |
|:---|:---|:---|
| Quoted market price on valuation date | $0.169 - $0.23 | $0.169 - $0.23 |
| Exercise prices | $| 0.12 |
| Range of expected term | 1.55 Years – 2.49 Years | 1.55 Years – 2.49 Years |
| Range of market volatility: |  |  |
| Range of equivalent volatility | 215.12% - 275.73% | 215.12% - 275.73% |
| Range of interest rates | 0.20% - 0.47% | 0.20% - 0.47% |

---

*Warrants*

As of December 31, 2022 and June 30, 2022, the Company had 105,512,161 and 55,512,161 warrants outstanding respectively. The warrants were issued in connection with the Convertible Notes (See Note 6). The warrants have a term of two to five years and an exercise price range from $0.1187 to $.025. The Company evaluated the warrants under ASC 815 Derivatives and Hedging ("ASC 815") and determined that they did not require liability classification. The warrants were recorded in additional paid-in capital under their aggregate relative fair value of $2,777,081. During the year ended June 30, 2022, holders of warrants exercised warrants for 4,305,000 shares of common stock for aggregate proceeds of $128,550. As of December 31, 2022 and June 30, 2022, the weighted average remaining useful life of the warrants was 4.0.

---

| |
|:---|
| F-20 |
| *[**Table of Contents**](#TOCF)* |

---

**NOTE 10 - NON-CONTROLLING INTEREST**

*AAT membership unit adjustment*

On May 12, 2021, on further advice of counsel and in good faith**,** the Company returned 3,600,000 membership units of American Aviation Technologies, LLC to a former shareholder, which was his consideration provided in the Share Exchange between American Aviation Technologies, LLC and Xeriant, Inc. As a result, this former shareholder was restored to his original shareholding position in American Aviation Technologies, LLC.

*AAT Subsidiary*

On May 12, 2021, the Company's position in American Aviation Technologies, LLC was reduced to 64%, and therefore the subsidiary is now classified as majority owned.

**NOTE 11 – SUBSEQUENT EVENTS**

Subsequent to December 31, 2022 and up to the date of this filing, the Company issued five 10 percent convertible notes totaling $130,000. These notes are convertible into the Company's common shares at a 25 percent discount to the prospective IPO share price. In conjunction with these notes, the Company issued 1,300,000 5-year warrants to the Company's purchase common shares at $0.09 per share.

An S-1 Registration Statement was filed on January 18, 2023, for the purpose of raising capital for the Company to execute its business plan.

---

| |
|:---|
| F-21 |
| *[**Table of Contents**](#TOCF)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion of our financial condition and results of operations should be read in conjunction with the audited and unaudited financial statements and the notes to those statements included elsewhere in this Report. This discussion contains forward-looking statements that involve risks and uncertainties. You should specifically consider the various risk factors identified in this Report that could cause actual results to differ materially from those anticipated in these forward-looking statements.*

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward looking statements, including without limitation, statements related to our plans, strategies, objectives, expectations, intentions and adequacy of resources. Investors are cautioned that such forward-looking statements involve risks and uncertainties including without limitation the following: (i) our plans, strategies, objectives, expectations and intentions are subject to change at any time at our discretion; (ii) our plans and results of operations will be affected by our ability to manage growth; and (iii) other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.

In some cases, you can identify forward-looking statements by terminology such as ''may,'' ''will,'' ''should,'' ''could,'' ''expects,'' ''plans,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''predicts,'' ''potential,'' or ''continue'' or the negative of such terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We are under no duty to update any of the forward-looking statements after the date of this Report.

This section of the report should be read together with Footnotes of the Company audited financials for the year ended June 30, 2022. The unaudited statements of operations for the six months ended December 31, 2022 and 2021 are compared in the sections below.

**Executive Summary**

Xeriant, Inc. is dedicated to the acquisition, development and commercialization of transformative technologies, including eco-friendly specialty materials which can be successfully deployed and integrated across multiple industry sectors, and disruptive innovations related to the emerging aviation market called Advanced Air Mobility, which include next-generation aircraft. We seek to partner with and acquire strategic interests in visionary companies that accelerate this mission. The Company is located at the Research Park at Florida Atlantic University in Boca Raton, Florida.

<u>JV with XTI Aircraft</u>

On May 31, 2021, the Company entered into a Joint Venture Agreement (the "Agreement") with XTI Aircraft Company ("XTI"), a Delaware corporation, to form a new company, called Eco-Aero, LLC (the "JV"), a Delaware limited liability company, with the purpose of completing the preliminary design of XTI's TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff, and landing (eVTOL) fixed wing aircraft. Under the Agreement, Xeriant is contributing capital, technology, and strategic business relationships, and XTI is contributing intellectual property licensing rights and know-how. XTI and the Company each own 50 percent of the JV. The JV is managed by a management committee consisting of five members, three appointed by the Company and two by XTI. The Agreement was effective on June 4, 2021, with an initial deposit of $1 million into the JV. Xeriant's financial commitment is up to $10 million, contributed as needed based on the aircraft development timeline and budget.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#tocc)* |

---

The Company analyzed the transaction under ASC 810 Consolidation, to determine if the joint venture classifies as a Variable Interest Entity ("VIE"). The Joint Venture qualifies as a VIE based on the fact the JV does not have sufficient equity to operate without financial support from Xeriant. According to ASC 810-25-38, a reporting entity shall consolidate a VIE when that reporting entity has a variable interest (or combination of variable interests) that provides the reporting entity with a controlling financial interest on the basis of the provisions in paragraphs 810-10-25-38A through 25-38J. The reporting entity that consolidates a VIE is called the primary beneficiary of that VIE. According to the JV operating agreement, the ownership interests are 50/50. However, the agreement provides for a Management Committee of five members. Three of the five members are from Xeriant. Additionally, Xeriant has the right to invest up to $10,000,000 into the JV. As such, Xeriant has substantial capital at risk. Based on these two factors, the conclusion is that Xeriant is the primary beneficiary of the VIE. Accordingly, Xeriant has consolidated the VIE.

*Recent Developments* 

<u>JV with Movychem</u>

On April 2, 2022 (Amended November 7, 2022), the Company entered into a Joint Venture Agreement with Movychem s.r.o., a Slovakian limited liability company setting forth the terms for the establishment of a joint venture (the "Joint Venture") to develop applications and commercialize a series of flame-retardant products in the form of polymer gels, powders, liquids and pellets derived from technology developed by Movychem under the name Retacell<sup>™</sup>. The Joint Venture is organized as a Florida limited liability company under the name Ebenberg, LLC and is owned 50% by each of the Company and Movychem.

For its capital contribution to the Joint Venture, pursuant to a Patent and Exclusive License and Assignment Agreement (the "Patent Agreement"), Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell exclusive of all patents, and the Company is contributing the amount of $2,600,000 payable (a) $600,000 at the rate of $25,000 per month over a 24 month period and (b) $2,000,000 within five business days of a closing of a financing in which the Company receives net proceeds of at least $3,000,000 but in no event later than February 15, 2023. The Company is currently in discussions with Movychem with the intent of extending the February 15, 2023 date. At such time as the Company makes its $2,000,000 payment (and assuming the Company is current with its then monthly capital contributions), pursuant to the Patent Agreement, Movychem will transfer all of its rights, title and interest to all of the patents related to Retacell for an amount equal to aggregate cash contributions of the Company to the Joint Venture plus 40% of all royalty payments received by the Joint Venture for the licensing of Retacell products. Pending assignment of the patents to the Joint Venture, pursuant to the Patent Agreement, Movychem has granted to the Joint Venture an exclusive worldwide license under the patents.

Concurrently with the execution of the Joint Venture Agreement, the Joint Venture has entered into a Services Agreement (the "Services Agreement") with the Company pursuant to which the Company will provide to the Joint Venture technical services related to the exploitation of the Retacell intellectual property and corporate, marketing. business development, communications and administrative services as requested by the Joint Venture in exchange for 40% of all royalty payments received by the Joint Venture for the licensing of Retacell products.

Under the Joint Venture Agreement, the Company has agreed to grant to certain individuals affiliated with Movychem five-year warrants (the "Warrants") to purchase an aggregate of 170,000,000 shares of the Company's common stock at an exercise price of $0.01 per share with vesting depending on the satisfaction of various milestones as described therein.

The Joint Venture Agreement grants to Movychem the right to dissolve the Joint Venture in the event that the Company fails to make any of its capital contributions in which case the Joint Venture will be required to grant back to Movychem all joint venture intellectual property and the assignment to Movychem of any outstanding licenses. Additionally, the Services Agreement will be amended to provide that the 40% of royalties to be paid by to the Company will be limited to licensees who were first introduced to the Joint Venture or Movychem, as the case may be.

The Company analyzed the transaction under ASC 810 Consolidation, to determine if the joint venture classifies as a Variable Interest Entity ("VIE"). The Joint Venture qualifies as a VIE based on the fact the JV does not have sufficient equity to operate without financial support from both parties. According to ASC 810-25-38, a reporting entity shall consolidate a VIE when that reporting entity has a variable interest (or combination of variable interests) that provides the reporting entity with a controlling financial interest on the basis of the provisions in paragraphs 810-10-25-38A through 25-38J. The reporting entity that consolidates a VIE is called the primary beneficiary of that VIE. According to the JV operating agreement, the ownership interests are 50/50 and the agreement provides for a Management Committee of five members. Two of the five members are from Xeriant and Movychem, respectively and one is appointed by mutual agreement of the parties. Movychem is transferring to the Joint Venture all of its interest to the know-how and intellectual property relating to Retacell exclusive of all patents, and the Company is contributing cash. As such, both parties do not have substantial capital at risk. Based on these two factors, the conclusion is that no one is the primary beneficiary of the VIE. Accordingly, Xeriant has not consolidated the VIE.

As of December 31, 2022 and June 30, 2022, the Company contributed $280,656 and $115,356 to the joint venture, respectively.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#tocc)* |

---

 *Litigation*

On September 1, 2021, Xeriant Inc. brought a cause of action in the Southern District of Florida against a former shareholder for claims, including but not limited to, breach of contract, misrepresentation, and asserting claims to recoup monetary and in-kind distributions made to the shareholder by the Company. The defendant submitted an affirmative defense and counterclaim on October 29, 2021.

***Three months ended December 31, 2022 compared to the three months ended December 31, 2021***

*Sales and marketing expenses*

Total sales and marketing expenses were $1,943 and $46,623 for the three months ended December 31, 2022 and 2021, respectively. During the three months ended December 31, 2022 the Company's sales and marketing expenses were associated with social media marketing campaigns, events and press releases.

*General and administrative expenses*

Total general and administrative expenses were $340,508 and $1,120,250 for the three months ended December 31, 2022 and 2021, respectively. In the prior period, there were increased expenses due to stock issuances related to consulting fees and advisory board fees.

*Professional Fees*

Total professional fees were $78,568 and $102,484 for the three months ended December 31, 2022 and 2021, respectively. The decrease was primarily due to less legal fees in the current period.

*Related Party Consulting Fees*

Total related party consulting fees were $118,000 and $130,925 for the three months ended December 31, 2022 and 2021, respectively. The related party consulting fees for the three months ended consisted of (i) $55,000 to Ancient Investments, LLC, a company owned by Keith Duffy, CEO and Scott Duffy, Executive Director of Operations, (ii) $21,000 for AMP Web Services, LLC, a company owned by Pablo Lavigna, CIO, $32,000 to Edward DeFeudis, Director, and (iii) $10,000 for Keystone Business Development Partners, LLC, a company owned by Brian Carey, CFO. The consulting fees for December 31, 2021 consisted of i) $76,425 to Ancient Investments, LLC, a company owned by Keith Duffy, CEO and Scott Duffy, Executive Director of Operations, (ii) $19,000 for AMP Web Services, LLC, a company owned by Pablo Lavigna, CIO, $28,000 to Edward DeFeudis, Director, and (iii) $7,500 for Keystone Business Development Partners, LLC, a company owned by Brian Carey, CFO.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#tocc)* |

---

*Research and Development Expenses*

Total research and development expenses were $0 and $2,859,644 for the three months ended December 31, 2022 and 2021, respectively. These research and development expenses were in connection with our Eco-Aero, LLC joint venture with XTI Aircraft Company for funding the preliminary design phase in the development of an aircraft, called the TriFan 600. There were no expenses for the joint venture for the three months ended December 31, 2022. Research & Development Expenses relating to Movychem/Ebenberg JV are accounted for through Ebenberg, LLC.

*Other Income (Expenses)*

Total other expenses consist of amortization of debt discount related to convertible notes, interest expense related to convertible notes, and a loss on settlement of debt. Total other expenses were $755,343 for the three months ended December 31, 2022 compared to $1,266,560 for the year ended December 31, 2021. The decrease was primarily due to recording the amortization of debt discount from the Auctus convertible note signed in October 2021 and the loss on extinguishment of debt due to the Auctus Note modification.

*Net loss*

Total net loss was $1,294,362 for the three months ended December 31, 2022 compared to $5,526,486 for the three months ended December 31, 2021. The decrease was primarily related amortization of debt discount of $1,264,931 and $2,859,644 of research and development expenses in the prior period versus $0 in the current period.

***Six months ended December 31, 2022 compared to the six months ended December 31, 2021***

*Sales and marketing expenses*

Total sales and marketing expenses were $8,299 and $645,218 for the six months ended December 31, 2022 and 2021, respectively. During the six months ended December 31, 2022 the Company's sales and marketing expenses were associated with social media marketing campaigns, events and press releases.

*General and administrative expenses*

Total general and administrative expenses were $886,077 and $2,321,252 for the six months ended December 31, 2022 and 2021, respectively. In the prior period, there were increased expenses due to stock issuances related to consulting fees and advisory board fees.

*Professional Fees*

Total professional fees were $168,628 and $132,025 for the six months ended December 31, 2022 and 2021, respectively. The decrease was primarily due to more legal fees in the current period.

*Related Party Consulting Fees*

Total related party consulting fees were $212,000 and $213,425 for the six months ended December 31, 2022 and 2021, respectively. The related party consulting fees for the six months ended consisted of (i) $110,000 to Ancient Investments, LLC, a company owned by Keith Duffy, CEO and Scott Duffy, Executive Director of Operations, (ii) $35,000 for AMP Web Services, LLC, a company owned by Pablo Lavigna, CIO, $52,000 to Edward DeFeudis, Director, and (iii) $15,000 for Keystone Business Development Partners, LLC, a company owned by Brian Carey, CFO. The consulting fees for December 31, 2021 consisted of i) $109,425 to Ancient Investments, LLC, a company owned by Keith Duffy, CEO and Scott Duffy, Executive Director of Operations, (ii) $37,000 for AMP Web Services, LLC, a company owned by Pablo Lavigna, CIO, $52,000 to Edward DeFeudis, Director, and (iii) $15,000 for Keystone Business Development Partners, LLC, a company owned by Brian Carey, CFO.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#tocc)* |

---

*Research and Development Expenses*

Total research and development expenses were $0 and $5,200,219 for the six months ended December 31, 2022 and 2021, respectively. These research and development expenses were in connection with our Eco-Aero, LLC joint venture with XTI Aircraft Company for funding the preliminary design phase in the development of an aircraft, called the TriFan 600. There were no expenses for the joint venture for the six months ended December 31, 2022. Research & Development Expenses relating to Movychem/Ebenberg JV are accounted for through Ebenberg, LLC.

*Other Income (Expenses)*

Total other expenses consist of amortization of debt discount related to convertible notes, interest expense related to convertible notes, and a loss on settlement of debt. Total other expenses were $4,836,879 for the six months ended December 31, 2022 compared to $1,462,259 for the year ended December 31, 2021. The increase was primarily due to recording the amortization of debt discount from the Auctus convertible note signed in October 2021 and the loss on extinguishment of debt due to the Auctus Note modification.

*Net loss*

Total net loss was $6,111,883 for the six months ended December 31, 2022 compared to $9,974,398 for the six months ended December 31, 2021. The decrease was primarily related amortization of debt discount of $1,413,959 and $5,200,219 of research and development expenses in the prior period versus $0 of research and development expenses and $461,842 of amortization of debt discount in the current period. The difference was partially offset by the loss on extinguishment of debt in the amount of $4,259,987 for the current period.

**Liquidity and Capital Resources**

As of December 31, 2022, we had a cash balance of $119,593 and a working deficit of $5,947,132. Our net loss of $6,111,883 in the six months ended December 31, 2022 was mostly funded by proceeds raised from financings. We will need to raise working capital (or refinance existing short-term debt to long-term debt) to fund operations. Future equity financings may be dilutive to our stockholders. Alternative forms of future financings may include preferences or rights superior to our common stock. Debt financings may involve a pledge of assets and will rank senior to our common stock. We have historically financed our operations through best- efforts private equity and debt financings. We do not have any credit or equity facilities available with financial institutions, stockholders or third-party investors, and will continue to rely on best efforts financings. The failure to raise sufficient capital will likely cause us to cease operations.

During the six months ended December 31, 2022, our operating activities used $943,785 of net cash used compared to using $6,013,001 of net cash used in our operating activities during the six months ended December 31 2021. This difference primarily related to a decrease in stock-based compensation and stock issued for services offset by higher amortization of debt discount and loss on settlement of debt.

**Funding Strategy**

To date, our operations have been funded primarily through private investors. Some of these investors have verbally committed additional funding for the Company, as needed. We have had a number of discussions with broker-dealers regarding the funding required to execute the Company's business plan, which is to acquire and develop breakthrough technologies or business interests in those companies that have developed these technologies. An S-1 Registration Statement was filed on January 18, 2023, for the purpose of raising capital for the Company to execute its business plan. No assurance can be given that funds will be available, or, if available, will be on terms acceptable to The Company.

**Off Balance Sheet Items**

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as "special purpose entities" (SPEs).

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#tocc)* |

---

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

As a smaller reporting company, the Company has elected not to provide the disclosure required by this item.

**Item 4. Controls and Procedures.**

***Disclosure Controls and Procedures***

Our management is responsible for maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Registrant files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. In addition, the disclosure controls and procedures must ensure that such information is accumulated and communicated to the Registrant's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial and other required disclosures.

At December 31, 2022, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Exchange Act) was carried out under the supervision and with the participation of Keith Duffy our Chief Executive Officer and Brian Carey our Chief Financial Officer. Based on his evaluation of our disclosure controls and procedures, he concluded that at December 31, 2022, our disclosure controls and procedures are not effective due to material weaknesses in our internal controls over financial reporting.

***Changes in Internal Control Over Financial Reporting***

There has been no change in the Company's internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during the Company's most recent fiscal quarter ended December 31, 2022, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#tocc)* |

---

**PART II – OTHER INFORMATION**

**Item 1. Legal Proceedings**

None.

**Item 1A. Risk Factors**

Our business is subject to numerous risks and uncertainties including but not limited to those discussed in "Risk Factors" in our Annual Report on Form 10-K.

**Item 2. Unregistered Sales of Equity Securities**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

None.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#tocc)* |

---

**Item 6. Exhibits**

The following exhibits are filed herewith

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Document** |
| [31.1](xeri_ex311.htm) | [Certification of the principal executive officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](xeri_ex311.htm) |
| [31.2](xeri_ex312.htm) | [Certification of the principal financial officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](xeri_ex312.htm) |
| [32.1](xeri_ex321.htm) | [Certification of the principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](xeri_ex321.htm) |
| [32.2](xeri_ex322.htm) | [Certification of the principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](xeri_ex322.htm) |

---

---

| | |
|:---|:---|
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#tocc)* |

---

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **XERIANT, INC.** | **XERIANT, INC.** |
| Date: February 16, 2023 | By: | */s/ Keith Duffy* |
|  |  | Keith Duffy<br>Chief Executive Officer<br>(Principal Executive) |

---

---

| | | |
|:---|:---|:---|
| Date: February 16, 2023 | By: | */s/ Brian Carey* |
|  |  | Brian Carey<br>Chief Financial Officer |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND**

**PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO RULE 13a-14(a) UNDER THE EXCHANGE ACT**

I, Keith Duffy, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Xeriant, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Dated: February 16, 2023 | By: | */s/ Keith Duffy* |
|  |  | Keith Duffy  |
|  |  | Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER AND**

**PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO RULE 13a-14(a) UNDER THE EXCHANGE ACT**

I, Brian Carey, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Xeriant, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Dated: February 16, 2023 | By: | */s/ Brian Carey* |
|  |  | Brian Carey  |
|  |  | Chief Financial Officer (Principal Financial Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

**(18 U.S.C. SECTION 1350)**

In connection with the Quarterly Report of Xeriant, Inc., a Nevada corporation (the "Company"), on Form 10-Q for the quarter ended December 31, 2022, as filed with the Securities and Exchange Commission (the "Report"), Keith Duffy, Chief Executive Officer of the Company, does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. ss. 1350), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: February 16, 2023 | By: | */s/ Keith Duffy* |
|  |  | Keith Duffy |
|  |  | Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

**(18 U.S.C. SECTION 1350)**

In connection with the Quarterly Report of Xeriant, Inc., a Nevada corporation (the "Company"), on Form 10-Q for the quarter ended December 31, 2022, as filed with the Securities and Exchange Commission (the "Report"), Brian Carey, Chief Financial Officer of the Company, does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. ss. 1350), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: February 16, 2023 | By: | */s/ Brian Carey* |
|  |  | Brian Carey |
|  |  | Chief Financial Officer (Principal Financial Officer) |

---